Arthritis care & research · 2026
Clinical Characteristics and Concordance of Anti-MDA5 Antibodies: A Multicenter Australian Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ali Syed B, Khoo Thomas, Shivakumar Keeran, Caroll Adam, Hender Lauren, Beroukas Dimitra, Griggs Kim, Jin Celina, De Malmanche Theo, Day Jessica, Major Gabor, Limaye Vidya
Аннотация
OBJECTIVE: In Australia, anti-MDA5 antibodies are exclusively tested by a line immunoblot assay (LIA). The clinical concordance of an LIA-positive anti-MDA5 result is unclear. We aimed to describe the clinical features and determine the clinical concordance of patients with anti-MDA5 antibodies.
METHODS: Electronic records of a multisite cohort (patients with positive anti-MDA5 on LIA from three states in Australia from January 2017 to September 2024) were reviewed for clinical features of dermatomyositis (cutaneous manifestations, proximal weakness, interstitial lung disease [ILD]), laboratory investigations and other myositis autoantibodies, and imaging pertaining to the muscles and lungs.
RESULTS: Complete clinical data were available for 108 of 118 patients with anti-MDA5 antibodies. A positive test was determined to be clinically concordant in 21 of 108 (19.4%) patients; these patients had higher signal intensity than those with clinical discordance (52 vs 19.5; P < 0.0001). The median age was 65 years (interquartile range 48-74), and 67% were female. The cohort was predominantly White (n = 14), followed by Southeast Asian (n = 3), African (n = 3), and Middle Eastern (n = 1). All 21 patients with anti-MDA5 dermatomyositis had ILD; 7 of 9 with rapidly progressive ILD (RP-ILD) were deceased at time of review. Patients with RP-ILD had higher ferritin levels (1,226 vs 262 μg/L; P < 0.05) and a higher neutrophil to lymphocyte ratio (4.1 vs 2.6; P < 0.05) than patients without RP-ILD. Pneumomediastinum developed in 7 of 21 (33%); of these, 6 had RP-ILD, and 4 subsequently died. Other manifestations included myositis (n = 8), cutaneous features (n = 14), polyarthritis (n = 6), and myocarditis (n = 1).
CONCLUSION: Higher anti-MDA5 signal intensity on LIA was associated with greater clinical concordance. Pneumomediastinum is common and associated with high mortality.
METHODS: Electronic records of a multisite cohort (patients with positive anti-MDA5 on LIA from three states in Australia from January 2017 to September 2024) were reviewed for clinical features of dermatomyositis (cutaneous manifestations, proximal weakness, interstitial lung disease [ILD]), laboratory investigations and other myositis autoantibodies, and imaging pertaining to the muscles and lungs.
RESULTS: Complete clinical data were available for 108 of 118 patients with anti-MDA5 antibodies. A positive test was determined to be clinically concordant in 21 of 108 (19.4%) patients; these patients had higher signal intensity than those with clinical discordance (52 vs 19.5; P < 0.0001). The median age was 65 years (interquartile range 48-74), and 67% were female. The cohort was predominantly White (n = 14), followed by Southeast Asian (n = 3), African (n = 3), and Middle Eastern (n = 1). All 21 patients with anti-MDA5 dermatomyositis had ILD; 7 of 9 with rapidly progressive ILD (RP-ILD) were deceased at time of review. Patients with RP-ILD had higher ferritin levels (1,226 vs 262 μg/L; P < 0.05) and a higher neutrophil to lymphocyte ratio (4.1 vs 2.6; P < 0.05) than patients without RP-ILD. Pneumomediastinum developed in 7 of 21 (33%); of these, 6 had RP-ILD, and 4 subsequently died. Other manifestations included myositis (n = 8), cutaneous features (n = 14), polyarthritis (n = 6), and myocarditis (n = 1).
CONCLUSION: Higher anti-MDA5 signal intensity on LIA was associated with greater clinical concordance. Pneumomediastinum is common and associated with high mortality.